ChromaDex Corporation 10-K Summary
Business Context and Reporting Period
Company: ChromaDex Corporation (formerly Cody Resources, Inc. following a reverse merger in June 2008).
Reporting Period: Fiscal year ended January 3, 2009.
Business Overview: ChromaDex supplies phytochemical reference standards, reference materials, and contract services to the dietary supplement, nutraceutical, food, beverage, pharmaceutical, and cosmetic markets. The company operates through subsidiaries ChromaDex, Inc. and Chromadex Analytics, Inc., with headquarters in Irvine, California, and a laboratory facility in Boulder, Colorado. The core strategy involves leveraging intellectual property (IP) to license "green" mass-marketable products and generate royalty payments.
Key Financial Metrics
| Metric | Year Ended Jan 3, 2009 | Year Ended Dec 29, 2007 |
|---|---|---|
| Net Sales | $4,506,301 | $4,754,073 |
| Gross Profit | $1,231,501 | $1,631,612 |
| Gross Margin | 27.3% | 34.3% |
| Operating Loss | $(2,068,033) | $(177,720) |
| Net Loss | $(2,104,476) | $(189,875) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.01) |
| Cash and Equivalents (Ending) | $1,125,504 | $303,785 |
| Net Cash Used in Operating Activities | $(1,921,371) | $144,827 (Provided) |
| Net Cash Provided by Financing Activities | $3,238,897 | $(175,873) |
Liquidity and Debt: As of January 3, 2009, the company held $1.1 million in cash. Total current liabilities were $2.07 million, including $1.18 million in deferred compensation due to officers. Capital lease obligations totaled $152,765. The company raised approximately $4.2 million in net proceeds from a private placement during the fiscal year.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 5% to $4.5 million, attributed to reduced customer spending on research and development due to the global economic recession.
- Margin Compression: Gross profit declined 25% to $1.2 million. Cost of sales increased 5% despite lower sales, driven by fixed labor and overhead costs that did not scale down with revenue.
- Expense Surge: Operating expenses increased significantly. Sales and marketing expenses rose 86% (to $720k) due to catalog distribution and staff expansion. General and administrative expenses rose 81% (to $2.6 million), primarily due to one-time legal and accounting costs (~$640k) associated with the reverse merger and public company compliance.
- Loss Expansion: Net loss widened from $190k to $2.1 million, reflecting the combination of lower gross margins and higher operating costs.
Guidance, Outlook, and Risks
Outlook: Management believes current cash reserves ($1.1 million) are sufficient to fund operations for approximately ten months (through Q3 2009). The company anticipates needing additional financing to execute long-term strategic plans, including the establishment of a GMP-compliant pilot plant and expansion of chemical libraries.
Management Commentary: The company is capitalizing on FDA Good Manufacturing Practices (GMP) regulations for dietary supplements, which require enhanced quality control, driving demand for reference standards. However, enforcement uncertainty remains a risk.
Risks and Contingencies:
- Liquidity Risk: The company has a history of operating losses and may need to raise additional capital. Failure to secure financing could force delays in product expansion or curtailment of operations.
- Market Risk: Dependence on customer R&D budgets, which are sensitive to economic conditions and government funding cycles.
- Regulatory Risk: Changes in FDA or FTC regulations regarding dietary supplements and advertising could impact demand for services.
- Stock Liquidity: Common stock trades on the OTC Bulletin Board and is subject to SEC "Penny Stock" rules, which may limit trading activity and liquidity.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $1.1 million cash balance against the stated 10-month operating plan and the timeline for potential new financing.
- Deferred Compensation: Note the $1.18 million liability "Due to officers," representing deferred salaries for founders, which is a significant non-cash liability on the balance sheet.
- One-Time Costs: Confirm the impact of the ~$640,000 in merger-related legal and accounting fees on the 2009 operating loss to assess normalized operating performance.
- Revenue Concentration: Review the dependency on international sales (approx. $1.4 million or 32% of total revenue) and the stability of key distributors.
- Stock Dilution: Monitor the potential for dilution from the 3.3 million outstanding options and 2 million warrants, as well as future equity offerings required for capital needs.